



MAR 27 2000

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

#38

David T. Read
Acting Director Regulatory Policy Staff, CDEV
Food and Drug Administration
1451 Rockville Pike, HFD-7
Rockville, MD 20852


Dear Mr. Read:

The attached application for interim patent term extension of U.S. Patent No. 4,373,527 was filed on January 28, 2000, under 35 U.S.C. § 156(d)(5).

The assistance of your Office is requested in confirming that the product identified in the application, Minimed 2007, is subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g)(3)(B)(ii).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156(d)(5) only if an application under section 515 of the Federal Food, Drug and Cosmetic Act was initially submitted prior to January 28, 2000 for the product Minimed 2007.

Inquiries regarding this communication should be directed to the undersigned at (703) 306-3159 (telephone) or (703)872-9411 (facsimile).



Karin Tyson
Senior Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Francis A. Cooch
Office of Patent Counsel
Johns Hopkins University
Applied Physics Laboratory
11100 Johns Hopkins Road/Laurel MD 20723-6099

kt